Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aytu Biopharma (AYTU) Gross Margin (2016 - 2026)

Aytu Biopharma has reported Gross Margin over the past 12 years, most recently at 63.46% for Q4 2025.

  • Quarterly Gross Margin fell 303.0% to 63.46% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 66.84% through Dec 2025, down 510.0% year-over-year, with the annual reading at 69.04% for FY2025, 621.0% down from the prior year.
  • Gross Margin was 63.46% for Q4 2025 at Aytu Biopharma, down from 66.14% in the prior quarter.
  • Over five years, Gross Margin peaked at 77.89% in Q4 2023 and troughed at 48.12% in Q2 2021.
  • The 5-year median for Gross Margin is 65.81% (2022), against an average of 64.13%.
  • Year-over-year, Gross Margin tumbled -1621bps in 2021 and then soared 1782bps in 2024.
  • A 5-year view of Gross Margin shows it stood at 53.18% in 2021, then grew by 24bps to 65.81% in 2022, then rose by 18bps to 77.89% in 2023, then dropped by -15bps to 66.49% in 2024, then dropped by -5bps to 63.46% in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Gross Margin are 63.46% (Q4 2025), 66.14% (Q3 2025), and 67.75% (Q2 2025).